Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for CNTGF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning CNTGF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: CNTGF is a Strong Buy candidate.
CNTGF stock price ended at $0.11 on 星期五, after dropping 8.33%
On the latest trading day Jan 16, 2026, the stock price of CNTGF fell by 8.33%, dropping from $0.11 to $0.11. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.11 and a high of $0.11. On the latest trading day, the trading volume for CNTGF decreased by 2.0K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 200 shares were traded, with a market value of approximately $3.0M.